APP Pharmaceuticals is a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding.

Heparin Lock Flush Solution, USP is intended to maintain patency of an indwelling venipuncture device designed for intermittent injection or infusion therapy or blood sampling. The solution may also be used following initial placement of the device in the vein, after each injection of a medication or after withdrawal of blood for laboratory analysis.

John Ducker, president and CEO of APP, said: “The FDA clearance to market a preservative-free Heparin lock flush solution provides healthcare professionals with a safer alternative to maintain the patency of intravenous injection devices used in neonates and pediatric patients.”

Do you think the new solution benefit healthcare professionals?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.